Coronary Stenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Stenosis

MalaCards integrated aliases for Coronary Stenosis:

Name: Coronary Stenosis 12 54 44 15 17 70
Coronary Artery Stenosis 12 15


External Ids:

Disease Ontology 12 DOID:4248
MeSH 44 D023921
NCIt 50 C80427
SNOMED-CT 67 233970002
UMLS 70 C0242231

Summaries for Coronary Stenosis

MalaCards based summary : Coronary Stenosis, also known as coronary artery stenosis, is related to kawasaki disease and chlamydia, and has symptoms including angina pectoris An important gene associated with Coronary Stenosis is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Lipoprotein metabolism. The drugs Everolimus and Adenosine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, neutrophil and heart, and related phenotypes are Decreased free cholesterol and Decreased LDL uptake

Related Diseases for Coronary Stenosis

Diseases related to Coronary Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 590)
# Related Disease Score Top Affiliating Genes
1 kawasaki disease 30.8 NPPB IL6 CRP ALB
2 chlamydia 30.7 TLR4 IL6 CRP
3 coronary artery vasospasm 30.7 TNNI3 PIK3C2A CRP ACE
4 inferior myocardial infarction 30.6 TNNI3 PIK3C2A NPPB ACE
5 right bundle branch block 30.6 TNNI3 NPPB ACE
6 angina pectoris 30.6 TNNI3 PIK3C2A NPPB IL6 ICAM1 CRP
7 infective endocarditis 30.5 TNNI3 SERPINE1 IL6 CRP
8 anterolateral myocardial infarction 30.5 NPPB ACE
9 coronary thrombosis 30.5 VWF SERPINE1 CRP
10 intracranial embolism 30.4 VWF CRP ALB ACE
11 coronary aneurysm 30.4 IL6 CRP ALB
12 vasculitis 30.4 VWF IL6 ICAM1 CRP
13 subendocardial myocardial infarction 30.4 SERPINE1 PIK3C2A
14 ischemia 30.4 PON1 PIK3C2A NPPB ICAM1 CXCL12 ACE
15 syphilis 30.4 IL6 CRP ALB ACE
16 chlamydia pneumonia 30.4 TLR4 IL6 CRP APOE
17 ischemic colitis 30.4 SERPINE1 CRP ACE
18 takayasu arteritis 30.4 IL6 ICAM1 CRP
19 atrioventricular block 30.4 TNNI3 PIK3C2A NPPB ACE
20 atrial heart septal defect 30.3 TNNI3 NPPB CRP ALB ACE
21 cardiogenic shock 30.3 NPPB IL6
22 carotid stenosis 30.3 VWF ICAM1 CRP APOE ACE
23 mitral valve disease 30.3 TNNI3 NPPB CRP ACE
24 cardiac arrest 30.2 TNNI3 PIK3C2A NPPB ALB ACE
25 thrombocytosis 30.2 VWF IL6 CRP ALB
26 essential thrombocythemia 30.2 VWF SERPINE1 IL6 CRP
27 plague 30.2 TLR4 IL6 ALB
28 endocarditis 30.1 TNNI3 SERPINE1 PIK3C2A IL6 CRP ALB
29 hemopericardium 30.1 TNNI3 CRP
30 acute myocarditis 30.0 TNNI3 NPPB CRP ACE
31 left bundle branch hemiblock 30.0 TNNI3 PIK3C2A NPPB CRP ACE
32 antiphospholipid syndrome 30.0 VWF SERPINE1 PON1 CRP
33 proteasome-associated autoinflammatory syndrome 1 30.0 TLR4 IL6 ICAM1 CRP ALB
34 arteries, anomalies of 30.0 TNNI3 SERPINE1 IL6 ICAM1 CRP APOE
35 crohn's disease 29.9 TLR4 IL6 ICAM1 CRP ALB
36 atrial fibrillation 29.9 VWF NPPB CRP ACE
37 intermediate coronary syndrome 29.9 VWF TNNI3 PIK3C2A PCSK9 IL6 CRP
38 homocysteinemia 29.9 VWF SERPINE1 PON1 CRP APOE ALB
39 silent myocardial infarction 29.9 TNNI3 CRP APOB APOA1 ACE
40 tetralogy of fallot 29.8 TNNI3 NPPB CRP APOE ACE
41 mitral valve insufficiency 29.8 TNNI3 PIK3C2A NPPB CRP ALB ACE
42 carotid artery disease 29.8 PON1 CRP APOE APOB APOA1 ACE
43 myocarditis 29.8 TNNI3 TLR4 PIK3C2A NPPB IL6 ICAM1
44 pericarditis 29.7 TNNI3 NPPB IL6 CRP ALB ACE
45 aortic aneurysm, familial abdominal, 1 29.7 SERPINE1 IL6 ICAM1 CRP CETP APOE
46 pulmonary hypertension 29.7 VWF SERPINE1 NPPB IL6 CRP ALB
47 congestive heart failure 29.7 TNNI3 PIK3C2A NPPB IL6 CRP ALB
48 aortic valve insufficiency 29.7 VWF TNNI3 PON1 NPPB CRP ALB
49 anxiety 29.7 IL6 CRP APOE ACE
50 hyperuricemia 29.7 CRP APOB ALB

Graphical network of the top 20 diseases related to Coronary Stenosis:

Diseases related to Coronary Stenosis

Symptoms & Phenotypes for Coronary Stenosis

UMLS symptoms related to Coronary Stenosis:

angina pectoris

GenomeRNAi Phenotypes related to Coronary Stenosis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.65 CXCL12
2 Decreased LDL uptake GR00340-A-1 8.32 LPL

MGI Mouse Phenotypes related to Coronary Stenosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 ACE ALB APOA1 APOB APOE CRP
2 homeostasis/metabolism MP:0005376 10.22 ACE ALB APOA1 APOB APOE CRP
3 cellular MP:0005384 10.15 ALB APOA1 APOB APOE CXCL12 ICAM1
4 immune system MP:0005387 10.07 ACE ALB APOB APOE CRP CXCL12
5 adipose tissue MP:0005375 10.03 ACE APOE IL6 LPL PIK3C2A SCARB1
6 liver/biliary system MP:0005370 9.93 ACE ALB APOA1 APOB APOE CXCL12
7 mortality/aging MP:0010768 9.8 ACE ALB APOB APOE CXCL12 ICAM1
8 muscle MP:0005369 9.32 ALB APOB APOE CXCL12 ICAM1 IL6

Drugs & Therapeutics for Coronary Stenosis

Drugs for Coronary Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Adenosine Approved, Investigational Phase 4 58-61-7 60961
Nitric Oxide Approved Phase 4 10102-43-9 145068
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Iodine Approved, Investigational Phase 4 7553-56-2 807
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Ticagrelor Approved Phase 4 274693-27-5 9871419
Fenofibrate Approved Phase 4 49562-28-9 3339
Acebutolol Approved, Investigational Phase 4 37517-30-9 1978
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
Pindolol Approved, Investigational Phase 4 13523-86-9 4828
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
Labetalol Approved Phase 4 36894-69-6 3869
Nadolol Approved Phase 4 42200-33-9 39147
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Atenolol Approved Phase 4 29122-68-7 2249
Bisoprolol Approved Phase 4 66722-44-9 2405
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
Cadexomer iodine Experimental Phase 4 94820-09-4
27 Immunologic Factors Phase 4
28 Immunosuppressive Agents Phase 4
29 Tubulin Modulators Phase 4
30 Antimitotic Agents Phase 4
31 diuretics Phase 4
32 Anti-Inflammatory Agents Phase 4
33 isosorbide-5-mononitrate Phase 4
34 Chlorhexidine gluconate Phase 4
35 Hypoglycemic Agents Phase 4
36 Trace Elements Phase 4
37 Nutrients Phase 4
38 Micronutrients Phase 4
39 Anti-Infective Agents, Local Phase 4
40 Antibiotics, Antitubercular Phase 4
41 Anti-Infective Agents Phase 4
42 Anti-Bacterial Agents Phase 4
43 Antifungal Agents Phase 4
44 Analgesics Phase 4
45 Analgesics, Non-Narcotic Phase 4
46 Fibrinolytic Agents Phase 4
47 Antirheumatic Agents Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Antipyretics Phase 4

Interventional clinical trials:

(show top 50) (show all 280)
# Name Status NCT ID Phase Drugs
1 Comparison of Fractional Flow Reserve and Minimal Luminal Area by Intravascular Ultrasound in Evaluating Intermediate Coronary Artery Stenosis in Each Coronary Artery Unknown status NCT01133015 Phase 4
2 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
3 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT00402272 Phase 4
4 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT01171820 Phase 4
5 Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
6 A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis Completed NCT01513070 Phase 4 Quick-Acting Heart Reliever;Isosorbide Dinitrate;Placebo of Isosorbide Dinitrate;Aspirin Enteric-coated Tablets;Placebo of Quick-Acting Heart Reliever;Aspirin Enteric-coated Tablets
7 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
8 Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery Completed NCT00375063 Phase 4
9 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
10 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
11 Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01136876 Phase 4 Iopamidol;Iodixanol-320
12 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01137786 Phase 4 Non ionic contrast media comparator;Non ionic contrast media comparator
13 Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement Completed NCT01070420 Phase 4
14 Vision II: Non Randomized French Evaluation of GALILEO Intravascular Radiotherapy System in Patients With de Novo Coronary Arteries Lesions by Restenosis on Angioplasty or Restenosis on Endoprosthesis Completed NCT00180583 Phase 4
15 Excel Drug-Eluting Stent Pilot Clinical Registry Completed NCT00385905 Phase 4
16 Phase 4 Study of Pioglitazone on Neointima Volume and Inflammatory Markers in Diabetic Patients Completed NCT00494559 Phase 4 Pioglitazone;Placebo
17 Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT01200693 Phase 4
18 XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT) Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
19 Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth. A Clinical, Multi-center, Prospective, Non-Randomized Study Completed NCT00349895 Phase 4
20 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
21 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
22 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
23 SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT00697372 Phase 4
24 Contrast Enhancement on Coronary Computed Tomographic Angiography : Effects on Intra-Coronary Attenuation Using Low Iodine Concentrations While Maintaining Identical IDR (EICAR-Trial) Completed NCT02462044 Phase 4 240 mg Iodine;300 mg Iodine;370 mg Iodine
25 Fractional Flow Reserve - Guided Elective Coronary Angioplasty Using Paclitaxel - Eluting Balloons With Provisional Stent Implantation: A Phase 4 Feasibility Study With 6-Month Follow-up by Optical Coherence Tomography Completed NCT02120859 Phase 4
26 EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease. Completed NCT00531011 Phase 4
27 Pullback wIth Resting Full-Cycle Flow ratIO or Fractional Flow Reserve for the Prediction of Post-PCI Hemodynamic Outcomes. A Study in Patients With Diffuse Coronary Artery Disease Recruiting NCT04417634 Phase 4
28 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial Recruiting NCT02601157 Phase 4 3-months DAPT;1-year DAPT
29 The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial) Recruiting NCT02232360 Phase 4 Rosuvastatin and fenofibrate;Rosuvastatin alone
30 QUantitative Flow Ratio Or Angiography for the assessMent of nOn-culprit Lesions Recruiting NCT04808310 Phase 4
31 Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention Recruiting NCT03465644 Phase 4 Tailored antithrombotic strategy;Conventional antithrombotic strategy
32 Fractional Flow Reserve Derived From Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain Active, not recruiting NCT03187639 Phase 4
33 Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease Active, not recruiting NCT02100722 Phase 4
34 Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery: Safety and Feasibility Vanguard Study (BEEFBURGER Trial). Not yet recruiting NCT04788186 Phase 4 De-prescribe beta blocker therapy
35 Fractional Flow Reserve- And Intra-vascular Ultrasound-Guided Percutaneous Coronary Intervention With Drug-Eluting Stents in Intermediate Coronary Artery Lesion (FAVOR Study) Terminated NCT01175863 Phase 4
36 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Severe Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Terminated NCT01136915 Phase 4 Iopamidol 370;Iodixanol 320
37 The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study Terminated NCT01899235 Phase 4
38 Post-marketing Study Comparing the Efficacy and Safety of Firebird 2 Versus Cypher Sirolimus-eluting Stents in Treating Patients With Coronary Artery Disease in China Withdrawn NCT01328730 Phase 4
39 Optimal Predilatation Technique for BVS Implantation Unknown status NCT02946320 Phase 3
40 FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty Unknown status NCT01824030 Phase 3
41 Comparing the Safety and Efficacy of Cordimax and Xience V Drug-eluting Stents, for the Treatment of Coronary Heart Disease (CHD) in the Clinical Research of Real World Unknown status NCT03185221 Phase 3
42 Validation of Adjunctive Cilostazol According to CYP2C19 Polymorphism: Prospective, Randomized, Single-Center Trial: Unknown status NCT00891670 Phase 3 cilostazol;clopidogrel;aspirin
43 The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention: Comparison or Efficacy Between COroflex PLEASe ANd TaxusTM Stent Unknown status NCT00699543 Phase 3
44 The Randomized FADDY Study (FrActional Flow Reserve Guided Drug Coated Balloon Only Strategy in De Novo coronarY Lesions) Unknown status NCT03452904 Phase 3
45 Coronary Computed Tomographic Angiography in Emergency Department Chest Pain Patients at Intermediate Risk of Acute Coronary Syndrome Unknown status NCT00473863 Phase 3
46 Hybrid Sirolimus-eluting Stent With Bioresorbable Polymer Versus Everolimus-eluting Stent With Durable Polymer for Total Coronary Occlusions in Native Coronary Arteries (PRISON-IV) Unknown status NCT01516723 Phase 3
47 SPIRIT PRIME Clinical Trial. Completed NCT00916370 Phase 3
48 A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures Completed NCT00042081 Phase 3 CGT003 (E2F Duplex Decoy)
49 A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions Completed NCT00180310 Phase 3
50 A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions Completed NCT00148356 Phase 2, Phase 3

Search NIH Clinical Center for Coronary Stenosis

Cochrane evidence based reviews: coronary stenosis

Genetic Tests for Coronary Stenosis

Anatomical Context for Coronary Stenosis

MalaCards organs/tissues related to Coronary Stenosis:

Endothelial, Neutrophil, Heart, Smooth Muscle, Eye, Monocytes, Pancreas

Publications for Coronary Stenosis

Articles related to Coronary Stenosis:

(show top 50) (show all 8788)
# Title Authors PMID Year
The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease. 54 61
19551315 2009
[Lipoprotein (a), D-Dimer and apolipoprotein A1 as markers of presence and severity of coronary disease]. 61 54
19386322 2009
Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. 54 61
18403458 2008
[Level of alpha-granule membrane protein (CD62P) in coronary heart disease]. 54 61
18353216 2008
[Association between plasma adiponectin levels and coronary lesion complexity]. 54 61
18087549 2007
[Predictive value of lipoprotein (a) and apolipoprotein A1 in patients with angiographycally evaluated coronary stenosis]. 54 61
17524316 2007
The 3'-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. 61 54
16829343 2006
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. 54 61
16084515 2006
Cholesteryl ester transfer protein gene polymorphisms and severity of coronary stenosis. 61 54
16553359 2006
Association of Leu125Val polymorphism of platelet endothelial cell adhesion molecule-1 (PECAM-1) gene & soluble level of PECAM-1 with coronary artery disease in Asian Indians. 61 54
15756041 2005
R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. 54 61
15488875 2004
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFRII in patients with coronary artery disease. 61 54
15495786 2004
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFalphaRII in patients with coronary artery disease. 54 61
14603993 2003
[Lipoprotein (a)--a mysterious factor in atherogenesis]. 54 61
12679978 2002
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. 61 54
11171785 2001
Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. 54 61
10487496 1999
Plasma lipids, lipoproteins and apolipoproteins and sudden cardiac death. 61 54
10335875 1999
Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. 54 61
9242969 1997
Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. 54 61
8960946 1996
Characteristics of vasospastic angina with exercised-induced ischemia--analysis of parameters of hemostasis and fibrinolysis. 54 61
8803721 1996
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. 61 54
7686453 1993
Morning blood pressure surge is associated with the severity of stable coronary artery disease in hypertensive patients. 61
33576694 2021
The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease. 61
33761594 2021
Diagnostic performance and limitation of quantitative flow ratio for functional assessment of intermediate coronary stenosis. 61
33246845 2021
Behavioural determinants impacting the adoption rate of coronary physiology. 61
33571564 2021
The atherosclerosis burden score. 61
33789435 2021
A clinical strategy to improve the diagnostic accuracy of 1.5-T non-contrast MR coronary angiography for detection of coronary artery disease: combination of whole-heart and volume-targeted imaging. 61
32975662 2021
Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes. 61
33787603 2021
Effect of Elevated Left Ventricular End Diastolic Pressure on Instantaneous Wave-Free Ratio and Fractional Flow Reserve Discordance. 61
33738015 2021
Ticagrelor versus clopidogrel for prevention of subclinical stent thrombosis detected by optical coherence tomography in patients with drug-eluting stent implantation-a multicenter and randomized study. 61
32326796 2021
The effect of myocardial injury on the clinical course of snake envenomation in South Korea. 61
32840397 2021
New transluminal attenuation gradient derived from dynamic coronary CT angiography: diagnostic ability of ischemia detected by 13N-ammonia PET. 61
33048244 2021
Effect of non-Newtonian fluid rheology on an arterial bypass graft: A numerical investigation guided by constructal design. 61
33535083 2021
Biosafety and efficacy evaluation of a biodegradable magnesium-based drug-eluting stent in porcine coronary artery. 61
33795781 2021
Prevalence of Abnormal Coronary Findings on Coronary Computed Tomography Angiography Among Young Adults Presenting With Chest Pain. 61
33003106 2021
Clinical Relevance of Coronary Computed Tomography Angiography Beyond Coronary Artery Stenosis. 61
33772488 2021
New susceptibility alleles associated with severe coronary artery stenosis in the Lebanese population. 61
33766035 2021
Sex-Related Differences in the Association of BMI and Pericardial Fat Volume With Coronary Atherosclerotic Markers in Young. 61
33207916 2021
Physiologic Assessment after Coronary Stent Implantation. 61
33655719 2021
Can Computed Fractional Flow Reserve Coronary CT Angiography (FFRCT) Offer an Accurate Noninvasive Comparison to Invasive Coronary Angiography (ICA)? "The Noninvasive CATH." A Comprehensive Review. 61
32624193 2021
From anatomy to function and then back to anatomy: invasive assessment of myocardial ischaemia in the catheterization laboratory based on anatomy-derived indices of coronary physiology. 61
33703856 2021
The association of polymorphism in PHACTR1 rs9349379 and rs12526453 with coronary artery atherosclerosis or coronary artery calcification. A systematic review. 61
33660664 2021
Down regulation of VDR gene expression in metabolic syndrome and atherosclerosis' patients: Cause or consequence? 61
33333229 2021
Aortic Valve Disease and Associated Complex CAD: The Interventional Approach. 61
33804391 2021
Reverse redistribution-like change on dipyridamole-stress 99mTc-tetrofosmin imaging in a patient with angiographically mild coronary artery stenosis. 61
33751474 2021
Relation between functional coronary artery stenosis and graft occlusion after coronary artery bypass grafting. 61
33431208 2021
Commentary: Functional coronary artery stenosis-How can we functionally apply this to the operating room? 61
33422311 2021
Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study. 61
32902743 2021
Relationship of epicardial fat volume with coronary plaque characteristics, coronary artery calcification score, coronary stenosis, and CT-FFR for lesion-specific ischemia in patients with known or suspected coronary artery disease. 61
33775790 2021
Investigation of serum ischemia-modified albumin levels in coronary artery disease patients. 61
33642712 2021

Variations for Coronary Stenosis

Expression for Coronary Stenosis

Search GEO for disease gene expression data for Coronary Stenosis.

Pathways for Coronary Stenosis

Pathways related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
6 11.64 TLR4 IL6 ICAM1 CXCL12
Show member pathways
Show member pathways
9 11.53 TLR4 IL6 ICAM1
10 11.4 TLR4 IL6 ICAM1
11 11.37 IL6 ICAM1 APOB
Show member pathways
13 11.22 IL6 ICAM1 APOA1
14 11.11 TLR4 APOE ACE
15 10.96 SCARB1 APOB APOA1

GO Terms for Coronary Stenosis

Cellular components related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.13 VWF SERPINE1 SCARB1 PON1 PIK3C2A ICAM1
2 cell surface GO:0009986 10.02 TLR4 SCARB1 PCSK9 LPL ICAM1 APOA1
3 collagen-containing extracellular matrix GO:0062023 9.97 VWF SERPINE1 ICAM1 CXCL12 APOE APOA1
4 early endosome GO:0005769 9.91 TLR4 PCSK9 APOE APOB APOA1
5 endoplasmic reticulum lumen GO:0005788 9.91 PCSK9 IL6 APOE APOB APOA1 ALB
6 blood microparticle GO:0072562 9.84 PON1 APOE APOA1 ALB
7 extracellular region GO:0005576 9.83 VWF SERPINE1 PON1 PCSK9 NPPB LPL
8 platelet alpha granule lumen GO:0031093 9.74 VWF SERPINE1 ALB
9 very-low-density lipoprotein particle GO:0034361 9.67 LPL APOE APOB APOA1
10 endocytic vesicle lumen GO:0071682 9.65 APOE APOB APOA1
11 low-density lipoprotein particle GO:0034362 9.63 APOE APOB APOA1
12 intermediate-density lipoprotein particle GO:0034363 9.58 APOE APOB APOA1
13 spherical high-density lipoprotein particle GO:0034366 9.56 PON1 APOA1
14 chylomicron GO:0042627 9.56 LPL APOE APOB APOA1
15 high-density lipoprotein particle GO:0034364 9.55 PON1 CETP APOE APOB APOA1
16 extracellular space GO:0005615 9.53 VWF SERPINE1 PON1 PCSK9 NPPB LPL
17 discoidal high-density lipoprotein particle GO:0034365 9.52 APOE APOA1

Biological processes related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.16 PON1 PCSK9 LPL CETP APOE APOB
2 post-translational protein modification GO:0043687 10.08 PCSK9 IL6 APOE APOB APOA1 ALB
3 receptor-mediated endocytosis GO:0006898 9.99 SCARB1 APOE APOB APOA1 ALB
4 cellular protein metabolic process GO:0044267 9.99 PCSK9 IL6 APOE APOB APOA1 ALB
5 cellular response to lipopolysaccharide GO:0071222 9.97 TLR4 SERPINE1 IL6 ICAM1
6 lipid transport GO:0006869 9.97 SCARB1 CETP APOE APOB APOA1
7 steroid metabolic process GO:0008202 9.95 PCSK9 CETP APOE APOB APOA1
8 platelet degranulation GO:0002576 9.94 VWF SERPINE1 APOA1 ALB
9 retinoid metabolic process GO:0001523 9.9 LPL APOE APOB APOA1
10 phospholipid metabolic process GO:0006644 9.87 PCSK9 LPL APOA1
11 positive regulation of interleukin-8 production GO:0032757 9.86 TLR4 SERPINE1 IL6
12 intermembrane lipid transfer GO:0120009 9.86 CETP APOE APOB APOA1
13 positive regulation of interleukin-1 beta production GO:0032731 9.85 TLR4 LPL IL6
14 cholesterol metabolic process GO:0008203 9.85 PON1 PCSK9 CETP APOE APOB APOA1
15 phospholipid transport GO:0015914 9.84 SCARB1 CETP APOA1
16 triglyceride metabolic process GO:0006641 9.83 PCSK9 LPL CETP APOE
17 positive regulation of chemokine production GO:0032722 9.82 TLR4 LPL IL6
18 low-density lipoprotein particle clearance GO:0034383 9.81 SCARB1 PCSK9 APOB
19 positive regulation of cholesterol efflux GO:0010875 9.8 PON1 APOE APOA1
20 phosphatidylcholine metabolic process GO:0046470 9.8 PON1 CETP APOA1
21 low-density lipoprotein particle remodeling GO:0034374 9.79 CETP APOE APOB
22 cholesterol efflux GO:0033344 9.78 SCARB1 APOE APOB APOA1
23 chylomicron assembly GO:0034378 9.76 APOE APOB APOA1
24 lipoprotein metabolic process GO:0042157 9.76 PCSK9 APOE APOB APOA1
25 high-density lipoprotein particle clearance GO:0034384 9.75 SCARB1 APOE APOA1
26 cholesterol transport GO:0030301 9.73 SCARB1 CETP APOB APOA1
27 cholesterol catabolic process GO:0006707 9.71 SCARB1 APOE
28 positive regulation of cholesterol storage GO:0010886 9.71 SCARB1 LPL APOB
29 reverse cholesterol transport GO:0043691 9.71 SCARB1 CETP APOE APOA1
30 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.7 TLR4 LPL
31 blood vessel endothelial cell migration GO:0043534 9.7 SCARB1 APOA1
32 neutrophil mediated immunity GO:0002446 9.7 IL6 ACE
33 negative regulation of lipid storage GO:0010888 9.69 IL6 CRP
34 positive regulation of cholesterol esterification GO:0010873 9.69 APOE APOA1
35 chylomicron remnant clearance GO:0034382 9.69 APOE APOB
36 regulation of Cdc42 protein signal transduction GO:0032489 9.68 APOE APOA1
37 cholesterol import GO:0070508 9.68 SCARB1 APOA1
38 very-low-density lipoprotein particle clearance GO:0034447 9.67 APOE APOB
39 lipoprotein catabolic process GO:0042159 9.67 APOE APOB
40 lipoprotein biosynthetic process GO:0042158 9.67 APOE APOB APOA1
41 positive regulation of phospholipid efflux GO:1902995 9.66 APOE APOA1
42 adhesion of symbiont to host GO:0044406 9.65 SCARB1 ICAM1
43 detection of lipopolysaccharide GO:0032497 9.65 TLR4 SCARB1
44 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.64 PCSK9 APOE
45 very-low-density lipoprotein particle remodeling GO:0034372 9.62 LPL CETP APOE APOA1
46 chylomicron remodeling GO:0034371 9.56 LPL APOE APOB APOA1
47 triglyceride homeostasis GO:0070328 9.55 SCARB1 LPL CETP APOE APOA1
48 high-density lipoprotein particle remodeling GO:0034375 9.35 SCARB1 CETP APOE APOA1 ALB
49 cholesterol homeostasis GO:0042632 9.17 SCARB1 PCSK9 LPL CETP APOE APOB

Molecular functions related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.92 SCARB1 CETP APOE APOA1 ALB
2 phospholipid binding GO:0005543 9.76 PON1 APOE APOB APOA1
3 amyloid-beta binding GO:0001540 9.71 TLR4 SCARB1 APOE APOA1
4 signaling receptor binding GO:0005102 9.7 TLR4 SERPINE1 NPPB LPL CXCL12 APOE
5 lipid transporter activity GO:0005319 9.61 APOE APOB APOA1
6 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.55 APOE APOA1
7 lipopolysaccharide receptor activity GO:0001875 9.54 TLR4 SCARB1
8 apolipoprotein binding GO:0034185 9.54 SCARB1 PCSK9 LPL
9 very-low-density lipoprotein particle receptor binding GO:0070326 9.51 PCSK9 APOE
10 low-density lipoprotein particle binding GO:0030169 9.5 SCARB1 PCSK9 CRP
11 triglyceride binding GO:0017129 9.49 LPL CETP
12 apolipoprotein receptor binding GO:0034190 9.48 PCSK9 APOA1
13 lipoprotein particle binding GO:0071813 9.43 LPL APOE APOA1
14 low-density lipoprotein particle receptor binding GO:0050750 9.26 PCSK9 CRP APOE APOB
15 intermembrane cholesterol transfer activity GO:0120020 8.92 CETP APOE APOB APOA1

Sources for Coronary Stenosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....